Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Drug Profile

Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Alternative Names: CRISPR/Cas9-based CAR-T cell therapies - Intellia Therapeutics/Novartis; CRISPR/Cas9-based haematopoietic stem cell therapies - Intellia Therapeutics/Novartis

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intellia Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Sickle cell anaemia

Most Recent Events

  • 22 Jun 2018 ERS genomics, the University of California and University of Vienna has patent protection for CRISPR/Cas9 technology for gene editing in the US and China
  • 19 Jun 2018 ERS Genomis and University of California has patent protection for CRISPR/Cas9 technology for gene editing in Japan, Australia, New Zealand, Mexico before June 2018
  • 11 Dec 2017 Pharmacodynamics data from a preclinical studies in Sickle cell disease presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top